A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

NCT ID: NCT03963414

Last Updated: 2023-08-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-25
• Study Completion Date: 2021-12-15

Brief Summary

This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).

Detailed Description

This Phase I, multicenter, study is designed to evaluate the safety and tolerability of durvalumab (anti-programmed death-ligand 1 [PD-L1] antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] antibody) in combination with intravenous (IV) carboplatin plus (+) etoposide in treatment naïve patients with extensive-stage small cell lung cancer (ES-SCLC) and performance status 2 (PS2). Eighteen patients with untreated ES-SCLC and PS2 will be enrolled. Cohort 1, which includes the first 6 subjects, will receive IV carboplatin and etoposide Q 3 weeks x 4 cycles. Durvalumab 1500 mg IV Q 3 weeks will be given with chemotherapy during cycles 3 and 4. This will be followed by durvalumab 1500 mg IV Q 4 weeks until disease progression. If 2 out of 6 patients have dose-limiting toxicities, then the study will be closed. Cohort 2, which will include 12 additional subjects, will receive chemotherapy Q 3 weeks x 4 cycles. Durvalumab 1500 mg IV + tremelimumab 75 mg IV Q 3 weeks will be given with chemotherapy during cycles 3 and 4, then durvalumab 1500 mg + tremelimumab 75 mg will be administered Q 3 weeks during cycles 5 and 6. This will be followed by durvalumab 1500 mg IV Q 4 weeks until disease progression.

Conditions

Small Cell Lung Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.

Group Type: EXPERIMENTAL

Durvalumab in combination with carboplatin and etoposide

Intervention Type: COMBINATION_PRODUCT

1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.

Cohort 2

Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.

Group Type: EXPERIMENTAL

Durvalumab + Tremelimumab in combination with carboplatin and etoposide

Intervention Type: COMBINATION_PRODUCT

1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.

Interventions

Durvalumab + Tremelimumab in combination with carboplatin and etoposide

1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.

Intervention Type: COMBINATION_PRODUCT

Durvalumab in combination with carboplatin and etoposide

1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

MEDI4736; MEDI4736

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years old at time of study entry (consent) and adult male or female (For Nebraska, ≥19 years old)

2. Histologically or cytologically confirmed ES-SCLC

3. Tumor biopsy or cytology should be obtained within 8 weeks of initiation of treatment.

4. Brain metastases; must be asymptomatic or treated and stable, off steroids for at least 1 month prior to study treatment.

5. Have not received any prior therapy for SCLC, except palliative radiation. If the patient received radiation, there must be measurable disease outside the radiation field.

6. Measurable disease or evaluable disease based on RECIST Version 1.1.

7. Eastern Cooperative Oncology Group ECOG = 2

8. Body weight > 30 kg

9. No active secondary malignancy. Patients with other prior malignancies will be included, provided they have been disease-free for at least five years.

10. Adequate hematologic and end organ function

11. Women of childbearing potential must have a pregnancy test (urine or serum) proven negative within 14 days prior to registration.

Exclusion Criteria

1. Participation in another clinical study with an investigational product during the last 28 days.

2. Any previous chemotherapy and /or immunotherapy for SCLC

3. Current or prior use (≤ 14 days before first doses of study drugs) of immunosuppressive medication.

4. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.

5. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP

6. History of leptomeningeal carcinomatosis

7. Paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic steroids or clinical symptomatology suggesting worsening of PNS

8. Active infection including tuberculosis, HIV, hepatitis B and C.

9. Active or prior documented autoimmune or inflammatory disorders

10. Uncontrolled cardiovascular disease

11. History of active primary immunodeficiency

12. Pregnant or lactating women

13. Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Apar Ganti, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Locations

University of Nebraska Medical Center

Omaha, Nebraska, United States

Countries

United States

Other Identifiers

0275-19-FB

Identifier Type: -

Identifier Source: org_study_id